HeXun Biosciences Cash Flow Statement

Financials in millions TWD. Fiscal year is January - December.

Millions TWD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2023	FY 2022	FY 2021
Period Ending	Jun '24 Jun 30, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Net Income	124.21	33.49	-5.19	-42.99
Depreciation & Amortization	20.91	19.1	14.19	11.43
Other Amortization	1.2	1.2	0.53	0.48
Loss (Gain) From Sale of Assets	0.06	0.05	-0.02	-0.2
Stock-Based Compensation	-	-	0.3	-
Other Operating Activities	-0.15	-0.07	-0.05	0.47
Change in Accounts Receivable	-82.81	-17.3	-4.98	-
Change in Inventory	-4.5	-4.6	-	-
Change in Accounts Payable	4.4	-0.8	0.42	-4.3
Change in Unearned Revenue	-6.51	-3.37	5.1	-
Change in Other Net Operating Assets	9.92	15.39	0.93	-0.39
Operating Cash Flow	66.73	43.09	11.23	-35.5
Operating Cash Flow Growth	342.71%	283.77%	-	-
Capital Expenditures	-36.46	-20.67	-1.23	-
Sale of Property, Plant & Equipment	-	-	0.13	8.84
Sale (Purchase) of Intangibles	-	-0.64	-5.96	-
Investment in Securities	-	-	-72	-
Other Investing Activities	-3.79	-3.97	-	-35.78
Investing Cash Flow	-40.25	-25.28	-79.05	-26.95
Long-Term Debt Repaid	-	-4.88	-2.46	-2.01
Net Debt Issued (Repaid)	-41.2	-4.88	-2.46	-2.01
Issuance of Common Stock	-	125	105	78
Other Financing Activities	-	-	-	-0.2
Financing Cash Flow	-41.2	120.12	102.54	75.79
Net Cash Flow	-14.72	137.93	34.72	13.34
Free Cash Flow	30.26	22.42	10	-35.5
Free Cash Flow Growth	625.06%	124.19%	-	-
Free Cash Flow Margin	12.80%	17.17%	20.22%	-
Free Cash Flow Per Share	0.66	0.49	0.27	-1.16
Cash Interest Paid	1.57	1.79	1.64	1.57
Levered Free Cash Flow	-18	9.68	0.46	-
Unlevered Free Cash Flow	-17.02	10.84	1.48	-
Change in Net Working Capital	75.34	5.26	0.75	-

Source: S&P Global Market Intelligence. Standard template. Financial Sources.